Lib­tayo, chemo com­bo clears lung can­cer tri­al two years ear­ly. But can it com­pete with Keytru­da?

With the sixth check­point in­hibitor on the US mar­ket, Re­gen­eron and Sanofi sought to cre­ate their own mar­ket for Lib­tayo by go­ing af­ter in­di­ca­tions oth­er drug­mak­ers hadn’t. That all changed in Feb­ru­ary when Lib­tayo scored an OK in non-small cell lung can­cer — the in­di­ca­tion that put Mer­ck’s Keytru­da on the map.

Now, the part­ners are look­ing to take on the heavy­weight champ in a chemother­a­py com­bi­na­tion for lung can­cer pa­tients with low­er PD-L1 ex­pres­sion, and they’re con­fi­dent they’ve got the da­ta to do it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER